| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00376662 | Osteoporosis | Drug: Hormone Replacement Therapy and Etidronate | British Thoracic Society | Phase 4 | 1992-08-01 | 2006-09-13 |
| NCT01585402 | Arterial Calcification Due to CD73-Deficiency (ACDC) | Drug: Etidronate|Procedure: MRI|Procedure: CT Scan|Procedure: ABI|Procedure: Treadmill|Procedure: Dexa Scan|Procedure: Hand X-ray | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) | Phase 1 | 2012-04-09 | 2017-03-07 |
| NCT02673060 | Bone Metastasis | Drug: MBC-11 | Osteros Biomedica Ltd | Phase 1 | 2014-07-01 | 2016-03-28 |
| NCT01077817 | Esophageal Cancer|Squamous Cell Carcinoma|Adenocarcinoma | Drug: Alendronate|Drug: Etidronate|Drug: Ibandronate|Drug: Risedronate|Drug: Raloxifene | Merck Sharp & Dohme Corp.|World Health Information Science Consultants, LLC | 2010-02-01 | 2015-04-27 |
| NCT01215890 | Crohn's Disease|Low Bone Mineral Density | Drug: risedronate|Drug: placebo | University of Alberta | Phase 4 | | 2010-10-05 |
| NCT00679978 | Vertebral Fracture|Osteonecrosis|Rheumatic Diseases | Saitama Medical University | Phase 4 | 2001-01-01 | 2009-09-17 |
| NCT00261625 | End-Stage Renal Disease|Osteoporosis | Drug: alendronate | National Taiwan University Hospital | Phase 4 | 2005-08-01 | 2009-01-02 |
| NCT00062595 | Osteoporosis | Drug: phylloquinone (K1)|Drug: menatetranone (MK4) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eisai Co., Ltd. | Phase 3 | 2000-09-01 | 2016-05-16 |
| NCT00843466 | Hand Dermatosis | Other: Mild, moisturizing hand cleanser | Wake Forest University|Wake Forest University Health Sciences | | 2007-05-01 | 2017-01-26 |
| NCT02731040 | Atypical Femoral Fractures|Osteoporosis|Bisphosphonate Therapy | Drug: Bisphosphonate | Washington University School of Medicine | | 2016-04-01 | 2016-04-15 |
| NCT02744482 | Prosthesis Loosening | Drug: risedronate|Drug: placebo | University Hospital, Limoges | Phase 3 | 2016-05-01 | 2016-08-11 |
| NCT02106455 | Osseous Paget's Disease | Drug: Sodium risedronate | Takeda | | 2013-05-01 | 2016-08-31 |
| NCT02106442 | Osteoporosis | Drug: Sodium risedronate | Takeda | | 2013-05-01 | 2016-11-16 |
| NCT02089997 | Osteoporosis | Drug: Sodium risedronate | Takeda | | 2013-05-01 | 2016-07-14 |
| NCT01406444 | Anorexia Nervosa|Osteopenia|Osteoporosis | Drug: rhIGF-1|Drug: Risedronate|Drug: Placebo | Massachusetts General Hospital | | 2011-10-01 | 2017-01-19 |
| NCT01249261 | Postmenopausal Women With Osteoporosis | Drug: Risedronate|Drug: Placebo/Risedronate | Warner Chilcott | Phase 3 | 2001-10-01 | 2011-10-27 |
| NCT00918749 | Postmenopausal Osteoporosis | Drug: 150 mg|Drug: 75 mg|Drug: 100 mg | Warner Chilcott | Phase 2 | 2009-05-01 | 2015-06-01 |
| NCT00859027 | Prostate Cancer | Drug: risedronate|Drug: placebo | UConn Health|Proctor and Gamble/Aventis | Phase 4 | 2003-01-01 | 2013-06-28 |
| NCT00846196 | Osteoporosis | Drug: risedronate DR (Phase III clinical supply)|Drug: risedronate 35 mg DR (Commercial Tablet) | Warner Chilcott|Sanofi | Phase 1 | 2009-01-01 | 2011-10-07 |
| NCT00837746 | Osteoporosis | Drug: risedronate | Warner Chilcott|Sanofi | Phase 4 | 2003-04-01 | 2013-06-03 |
| NCT00772395 | Bone Loss | Drug: Risedronate|Drug: Placebo | Danderyd Hospital|Sanofi | Phase 4 | 2006-04-01 | 2014-09-18 |
